These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 2459218)

  • 1. CR2 ligands modulate human B cell activation.
    Bohnsack JF; Cooper NR
    J Immunol; 1988 Oct; 141(8):2569-76. PubMed ID: 2459218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymeric C3dg primes human B lymphocytes for proliferation induced by anti-IgM.
    Carter RH; Fearon DT
    J Immunol; 1989 Sep; 143(6):1755-60. PubMed ID: 2528579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes.
    Nemerow GR; McNaughton ME; Cooper NR
    J Immunol; 1985 Nov; 135(5):3068-73. PubMed ID: 2995485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL.
    Delibrias CC; Fischer E; Bismuth G; Kazatchkine MD
    J Immunol; 1992 Aug; 149(3):768-74. PubMed ID: 1386093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
    Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
    J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.
    Pernegger G; Schulz TF; Hosp M; Myones BL; Petzer AL; Eigentler A; Böck G; Wick G; Dierich MP
    Immunology; 1988 Oct; 65(2):237-41. PubMed ID: 2461345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes.
    Fischer E; Delibrias C; Kazatchkine MD
    J Immunol; 1991 Feb; 146(3):865-9. PubMed ID: 1703182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of the stimulation of complement receptors CR1 (CD35) and CR2 (CD21) on cell proliferation and intracellular Ca2+ mobilization of chronic lymphocytic leukemia B cells.
    Hivroz C; Fischer E; Kazatchkine MD; Grillot-Courvalin C
    J Immunol; 1991 Mar; 146(6):1766-72. PubMed ID: 1826011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C3 synthetic peptides support growth of human CR2-positive lymphoblastoid B cells.
    Servis C; Lambris JD
    J Immunol; 1989 Apr; 142(7):2207-12. PubMed ID: 2784456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD45 inhibition of human B cell proliferation depends on the nature of activation signals and the state of B cell activation. A study with anti-IgM and anti-CDw40 antibodies.
    Gruber MF; Bjorndahl JM; Nakamura S; Fu SM
    J Immunol; 1989 Jun; 142(12):4144-52. PubMed ID: 2470814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human B cell responsiveness to B cell growth factor after activation by phorbol ester and monoclonal anti-mu antibody.
    Suzuki T; Butler JL; Cooper MD
    J Immunol; 1985 Apr; 134(4):2470-6. PubMed ID: 2982946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic free calcium concentration.
    Tsokos GC; Lambris JD; Finkelman FD; Anastassiou ED; June CH
    J Immunol; 1990 Mar; 144(5):1640-5. PubMed ID: 2137840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro maturation of B cells in chronic lymphocytic leukemia. I. Synergistic action of phorbol ester and interleukin 2 in the induction of Tac antigen expression and interleukin 2 responsiveness in leukemic B cells.
    Kabelitz D; Pfeffer K; von Steldern D; Bartmann P; Brudler O; Nerl C; Wagner H
    J Immunol; 1985 Oct; 135(4):2876-81. PubMed ID: 2993419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes.
    Carter RH; Spycher MO; Ng YC; Hoffman R; Fearon DT
    J Immunol; 1988 Jul; 141(2):457-63. PubMed ID: 2968402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of signaling via the B cell antigen receptor by CD21, the receptor for C3dg and EBV.
    Luxembourg AT; Cooper NR
    J Immunol; 1994 Nov; 153(10):4448-57. PubMed ID: 7525704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signaling through CD19, Fc receptors or transforming growth factor-beta: each inhibits the activation of resting human B cells differently.
    Barrett TB; Shu GL; Draves KE; Pezzutto A; Clark EA
    Eur J Immunol; 1990 May; 20(5):1053-9. PubMed ID: 1694130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of B lymphocytes by Epstein-Barr virus/CR2 receptor interaction.
    Masucci MG; Szigeti R; Ernberg I; Hu CP; Torsteinsdottir S; Frade R; Klein E
    Eur J Immunol; 1987 Jun; 17(6):815-20. PubMed ID: 3036539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. gp140, a C3b-binding membrane component of lymphocytes, is the B cell C3dg/C3d receptor (CR2) and is distinct from the neutrophil C3dg receptor (CR4).
    Frade R; Myones BL; Barel M; Krikorian L; Charriaut C; Ross GD
    Eur J Immunol; 1985 Dec; 15(12):1192-7. PubMed ID: 3878789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphocytes stimulated by allogeneic B cell lines cleave the third component of complement and fix C3 fragments. Their nonspecific lytic capacity is elevated against complement receptor type 2-carrying targets.
    Ramos OF; Algarra I; Sármay G; Yefenof E; Gergely J; Klein E
    J Immunol; 1989 Jan; 142(1):217-23. PubMed ID: 2521233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human B cell activation. Effect of T cell cytokines on the physicochemical binding requirements for achieving cell cycle progression via the membrane IgM signaling pathway.
    Mongini PK; Highet PF; Inman JK
    J Immunol; 1995 Oct; 155(7):3385-400. PubMed ID: 7561033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.